Literature DB >> 17278920

Work disability in rheumatic diseases.

Edward Yelin1.   

Abstract

PURPOSE OF REVIEW: To review developments in the literature concerning work disability in the rheumatic diseases. RECENT
FINDINGS: There have been three sets of studies to emerge in the last year. In the first, several studies analyze alternative research methods to document work disability. The second set uses qualitative methods to identify the specific factors that affect the decision to leave work. The third set analyzes interventions to reduce work disability.
SUMMARY: The quantitative and qualitative studies concur on the importance of flexible working conditions as an important, if not the most important risk factor for work disability in a diverse array of rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278920     DOI: 10.1097/BOR.0b013e3280126b66

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  25 in total

1.  Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.

Authors:  Wilbert B van den Hout
Journal:  Nat Clin Pract Rheumatol       Date:  2008-12-23

2.  The impact of rheumatoid arthritis and biologics on employers and payers.

Authors:  Paresh Chaudhari
Journal:  Biotechnol Healthc       Date:  2008-07

Review 3.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

4.  Construct Validity and Scoring Methods of the World Health Organization: Health and Work Performance Questionnaire Among Workers With Arthritis and Rheumatological Conditions.

Authors:  Rawan AlHeresh; Michael P LaValley; Wendy Coster; Julie J Keysor
Journal:  J Occup Environ Med       Date:  2017-06       Impact factor: 2.162

Review 5.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Ahmed Kotb; Robin Christensen; Amy S Mudano; Lara J Maxwell; Nipam P Shah; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2016-05-13

6.  Impact of vasculitis on employment and income.

Authors:  Lillian Barra; Renée L Borchin; Cristina Burroughs; George C Casey; Carol A McAlear; Antoine G Sreih; Kalen Young; Peter A Merkel; Christian Pagnoux
Journal:  Clin Exp Rheumatol       Date:  2018-01-10       Impact factor: 4.473

7.  A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.

Authors:  Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell
Journal:  CMAJ       Date:  2009-11-02       Impact factor: 8.262

Review 8.  Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Amy S Mudano; Lara J Maxwell; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Maria E Suarez-Almazor; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 9.  Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2016-10       Impact factor: 4.592

10.  Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

Authors:  Jane T Osterhaus; Oana Purcaru; Lance Richard
Journal:  Arthritis Res Ther       Date:  2009-05-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.